DISCLOSURES
The authors have no conflicts of interest to declare.
REFERENCES
1. Robinson ES, Werth VP. The role of cytokines in the pathogenesis of cutaneous lupus erythematosus. Cytokine. 2015;73(2):326-334.
2. Hsieh SC, Tsai CY, Sun KH, et al. Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol. 1995;34(2):107-112.
3. Jandl RC, George JL, Dinarello CA, Schur PH. The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus. Clin Immunol Immunopathol. 1987;45(3):384-394.
4. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630-633.
2. Hsieh SC, Tsai CY, Sun KH, et al. Defective spontaneous and bacterial lipopolysaccharide-stimulated production of interleukin-1 receptor antagonist by polymorphonuclear neutrophils of patients with active systemic lupus erythematosus. Br J Rheumatol. 1995;34(2):107-112.
3. Jandl RC, George JL, Dinarello CA, Schur PH. The effect of interleukin 1 on IgG synthesis in systemic lupus erythematosus. Clin Immunol Immunopathol. 1987;45(3):384-394.
4. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630-633.
AUTHOR CORRESPONDENCE
Kristen I. Lo Sicco MD Kristen.LoSicco@nyulangone.org
